{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:22:26Z","timestamp":1795026146547,"version":"4.10.2"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study did not receive any specific funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12888-016-1049-5","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T11:02:18Z","timestamp":1475492538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":214,"title":["Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Varuni Asanka","family":"de Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chathurie","family":"Suraweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhashini S.","family":"Ratnatunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhubashinee","family":"Dayabandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimali","family":"Wanniarachchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveen","family":"Hanwella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"issue":"4","key":"1049_CR1","doi-asserted-by":"publisher","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","volume":"9","author":"M Bak","year":"2014","unstructured":"Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014;9(4):e94112.","journal-title":"PLoS One"},{"issue":"1","key":"1049_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2045125312464385","volume":"3","author":"E Papanastasiou","year":"2013","unstructured":"Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol. 2013;3(1):33\u201351.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"6","key":"1049_CR3","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.4088\/JCP.11m07246","volume":"73","author":"CJ Bushe","year":"2012","unstructured":"Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry. 2012;73(6):e749\u201355.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"1049_CR4","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1\u201393.","journal-title":"CNS Drugs"},{"issue":"6","key":"1049_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","volume":"101","author":"DM Taylor","year":"2000","unstructured":"Taylor DM, McAskill R. Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr Scand. 2000;101(6):416\u201332.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14740338.2015.974549","volume":"14","author":"R Musil","year":"2015","unstructured":"Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73\u201396.","journal-title":"Expert Opin Drug Saf"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1192\/bjp.171.6.502","volume":"171","author":"S Brown","year":"1997","unstructured":"Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502\u20138.","journal-title":"Br J Psychiatry"},{"issue":"10","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123\u201331.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0165-1781(01)00234-7","volume":"101","author":"KR Fontaine","year":"2001","unstructured":"Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277\u201388.","journal-title":"Psychiatry Res"},{"issue":"6","key":"1049_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","volume":"150","author":"CH Hennekens","year":"2005","unstructured":"Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115\u201321.","journal-title":"Am Heart J"},{"issue":"2","key":"1049_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1192\/bjp.bp.107.042853","volume":"193","author":"M Alvarez-Jimenez","year":"2008","unstructured":"Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193(2):101\u20137.","journal-title":"Br J Psychiatry"},{"issue":"10","key":"1049_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"U Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071\u201394.","journal-title":"Drugs"},{"issue":"1","key":"1049_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","volume":"6","author":"A Lee","year":"1998","unstructured":"Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6(1):47\u201353.","journal-title":"Obes Res"},{"key":"1049_CR14","volume-title":"Global guideline for Type 2 diabetes","author":"IDF Clinical Guidelines Task Force","year":"2005","unstructured":"IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation; 2005."},{"issue":"1","key":"1049_CR15","first-page":"27","volume":"121","author":"C Seifarth","year":"2013","unstructured":"Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27\u201331.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"12","key":"1049_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/0269881115613519","volume":"29","author":"VA Silva de","year":"2015","unstructured":"de Silva VA, Dayabandara M, Wijesundara H, Henegama T, Gunewardena H, Suraweera C, Hanwella R. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. J Psychopharmacol. 2015;29(12):1255\u201361.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"1049_CR17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","volume":"170","author":"LF Jarskog","year":"2013","unstructured":"Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS, for the METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032\u201340.","journal-title":"Am J Psychiatry"},{"key":"1049_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139.","journal-title":"Ann Intern Med"},{"key":"1049_CR19","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.","edition":"4"},{"key":"1049_CR20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.","edition":"5"},{"key":"1049_CR21","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organisation","year":"1992","unstructured":"World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: WHO; 1992."},{"key":"1049_CR22","first-page":"1","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin. Trials. 1996;17:1\u201312.","journal-title":"Trials"},{"key":"1049_CR23","unstructured":"The Nordic Cochrane Centre: Review Manager (RevMan) [ComputerProgram] Version 5.0. Copenhagen: The Cochrane Collaboration, Version 5.2.6 2012."},{"issue":"3","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"8","key":"1049_CR25","first-page":"1130","volume":"29","author":"S Arman","year":"2008","unstructured":"Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J. 2008;29(8):1130\u20134.","journal-title":"Saudi Med J"},{"issue":"8","key":"1049_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1176\/appi.ajp.2012.11091432","volume":"169","author":"RR Wu","year":"2012","unstructured":"Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, Wang J, Guo XF, Davis JM, Chan PK, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012;169(8):813\u201321.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1049_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.schres.2012.02.021","volume":"138","author":"M Wang","year":"2012","unstructured":"Wang M, Tong JH, Zhu G, Liang GM, Yan HF, Wang XZ. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012;138(1):54\u20137.","journal-title":"Schizophr Res"},{"issue":"2","key":"1049_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.2007.56-b","volume":"299","author":"RR Wu","year":"2008","unstructured":"Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185\u201393.","journal-title":"JAMA"},{"key":"1049_CR29","unstructured":"Comprehensive Meta-Analysis [Computer software Trial version]. Englewood: Biostat; 2014."},{"issue":"4","key":"1049_CR30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4103\/1735-1995.158262","volume":"20","author":"P Hebrani","year":"2015","unstructured":"Hebrani P, Manteghi AA, Behdani F, Hessami E, Rezayat KA, Marvast MN, Rezayat AA. Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J Res Med Sci. 2015;20(4):364\u201371.","journal-title":"J Res Med Sci"},{"issue":"3","key":"1049_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/070674370605100310","volume":"51","author":"T Baptista","year":"2006","unstructured":"Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arape Y, Martinez M, de Mendoza S, Teneud L, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006;51(3):192\u20136.","journal-title":"Can J Psychiatry"},{"issue":"1\u20133","key":"1049_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.schres.2007.03.029","volume":"93","author":"T Baptista","year":"2007","unstructured":"Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, Galeazzi T, Gutierrez MA, Servigna M, Davila A, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007;93(1\u20133):99\u2013108.","journal-title":"Schizophr Res"},{"issue":"1","key":"1049_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2009.05.007","volume":"113","author":"E Carrizo","year":"2009","unstructured":"Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, Valbuena D, Fernandez I, de Baptista EA, Baptista T. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14\u00a0week, double-blind, parallel group, placebo-controlled study. Schizophr Res. 2009;113(1):19\u201326.","journal-title":"Schizophr Res"},{"issue":"3","key":"1049_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1176\/appi.ajp.2007.07010079","volume":"165","author":"RR Wu","year":"2008","unstructured":"Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352\u20138.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1049_CR35","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.4088\/JCP.12m08186","volume":"74","author":"CH Chen","year":"2013","unstructured":"Chen CH, Huang MC, Kao CF, Lin SK, Kuo PH, Chiu CC, Lu ML. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74(5):e424\u201330.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1049_CR36","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1176\/ajp.2006.163.12.2072","volume":"163","author":"DJ Klein","year":"2006","unstructured":"Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072\u20139.","journal-title":"Am J Psychiatry"},{"key":"1049_CR37","doi-asserted-by":"publisher","DOI":"10.1037\/10510-004","volume-title":"Weighing the Options: Criteria for Evaluating Weight-Management Programs","author":"Institute of Medicine","year":"1995","unstructured":"Institute of Medicine. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington: National Academy Press; 1995."},{"issue":"2","key":"1049_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0033291709990407","volume":"40","author":"I Tarricone","year":"2010","unstructured":"Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40(2):187\u2013200.","journal-title":"Psychol Med"},{"issue":"6","key":"1049_CR39","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","volume":"34","author":"CC Chiu","year":"2010","unstructured":"Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):866\u201370.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"1049_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1176\/appi.ajp.159.4.655","volume":"159","author":"JA Morrison","year":"2002","unstructured":"Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002;159(4):655\u20137.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"1049_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/cap.2008.094","volume":"19","author":"L Shin","year":"2009","unstructured":"Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol. 2009;19(3):275\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"1049_CR42","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","volume":"40","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385\u2013403.","journal-title":"Schizophr Bull"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-016-1049-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-1049-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T09:25:12Z","timestamp":1692523512000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-016-1049-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1186\/s12888-016-1049-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]},"article-number":"341"}}